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Furthermore, the proportion of normal 
subjects with anti-Dsg3 IgG increased 
with increasing proximity of their place 
of residence to the endemic area. No 
apparent crossreactivity between anti-
Dsg1 and anti-Dsg3 IgG was found in 
the fogo selvagem patients. Although 
the authors detected anti-Dsg3 IgG in 
those patients with fogo selvagem, none 
of them developed any obvious clinical 
phenotype of PV, such as oral lesions. It 
is not clear why those patients with anti-
Dsg3 IgG in addition to anti-Dsg1 IgG 
do not show the clinical phenotype of 
mucocutaneous-type PV. A part of the 
reason could be that the quantities of 
pathogenic anti-Dsg3 IgG were insuffi-
cient to induce the PV phenotype, as the 
authors found that the intensity of immu-
noprecipitated Dsg3 was less strong than 
that of Dsg1.
Certainly, fogo selvagem provides a 
fascinating model in autoimmune dis-
eases. Now we know that an uniden-
tified environmental factor(s) triggers 
not only anti-Dsg1 IgG but also anti-
Dsg3 IgG autoantibodies. This finding 
offers new insight into the epidemio-
logy of fogo selvagem and provides 
a framework for better understanding 
of immunological mechanisms of the 
onset of autoimmune response against 
desmogleins in pemphigus.
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Pathways to the Development of 
Melanoma: A Complex Issue
Marianne Berwick1
The investigation of nevus distribution by anatomic site has led to interesting 
hypotheses of divergent pathways to the development of melanoma. However, 
such hypotheses must be viewed in all their complexity, and the paper by Randi 
et al. gives additional substance to this complexity.
Journal of Investigative Dermatology (2006) 126, 1932–1933. doi:10.1038/sj.jid.5700419
In this issue, Randi et al. (2006) report 
on a carefully conducted case-con-
trol study of melanoma conducted 
by a collaborative group, the Italian 
Group for Epidemiologic Research in 
Dermatology (GISED), from 1992 to 
1994. Dermatologists counted nevi on 
both cases and controls. The authors 
state that there was an effect of nevi at 
all sites, but no site-specific associa-
tion, except for the posterior trunk. They 
suggest that their interpretation of the 
data runs counter to the very interest-
ing hypothesis raised in 2003 by David 
Whiteman and his colleagues, who 
suggested different etiologic pathways 
for melanomas on the head and neck 
and melanomas on the trunk. Further 
genetic support for such a hypothesis 
has been found in the data presented by 
Curtin and his colleagues (Curtin et al., 
2005; Maldonado et al., 2003; Bastian 
et al., 2003) when they investigated 
somatic mutations in BRAF. However, it 
may be best to modify this hypothesis 
to state that different etiologic pathways 
may consist of (1) aberrant melanogen-
esis and (2) cumulative sun exposure 
among susceptible individuals. The 
difference here is that the pathways as 
suggested are similar, but the focus is 
on biology rather than anatomic site.
In evaluating the difference between 
the two alternative (although comple-
mentary) hypotheses, it is helpful to 
look at a table of subjects in three epi-
demiologic studies (Randi et al., 2006; 
Whiteman et al., 2003; Berwick et al., 
unpublished data) arranged by ana-
tomical site and to review several dif-
ferences among the studies (Table 1).
It is immediately obvious that there 
are important differences in the site dis-
tribution of nevi. These differences can in 
part, but not wholly, be explained by the 
oversampling used by Whiteman et al. 
(2003), because Randi et al. (2006) had 
a very much larger proportion of indi-
viduals with melanoma of the head and 
neck. In fact, a Spanish study by Ocaña-
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Riola et al. (2001) reported a similar 
proportion of head and neck melano-
mas, whereas both Berwick et al. and 
Cho et al. (2005), another American 
group, had a much smaller propor-
tion of head and neck melanomas. 
The distributional difference between 
the United States populations and the 
Mediterranean populations could pos-
sibly be due to genetic factors specific 
to these populations, differential sun 
exposure patterns, or selection bias — 
although the Spanish study was popu-
lation-based. In any case, the different 
distribution of melanomas by anatomic 
site among Mediterranean, Australian, 
and American populations should be 
investigated further.
More interesting is the difference in 
the mean or median numbers of nevi 
reported. Although the papers report 
numbers quite differently, the great dif-
ferences among countries are obvious. 
Of course, these are also probably due 
to the wide variation in the methods 
of counting and the proportion of the 
body counted. However, in Italy, the 
highest tertile for nevi on the trunk was 
“>10” (adding posterior and anterior 
trunk), whereas, in Australia, 44.8% 
of the nevi on the trunk and 24.7% on 
the head and neck were “>60” — a 
very large difference. A comparison 
of the median number of nevi in the 
Berwick et al. study and the Whiteman 
et al. (2003) study shows a sixfold dif-
ference between Connecticut and 
Australia, whereas a comparison of the 
mean number of nevi in the Berwick 
et al. study and the Randi et al. (2006) 
study shows a twofold difference. 
This is only a very general estimate, 
given the differences in anatomic sites 
accounted for. The point, however, 
should be clear that Australians have 
many more nevi than Italians and 
Americans — an unsurprising fact.
Why is that important for the study 
by Randi et al. (2006)? The hypothesis 
by Whiteman et al. (2003) of diver-
gent pathways for the development of 
melanoma has generated a great deal 
of interest and enthusiasm. The data 
of Curtin et al. (2005) clearly support 
this hypothesis. However, it is critical 
not to interpret these ideas too simplis-
tically — as I fear is happening. True 
population-based studies and larger 
studies will bear out the complexity of 
the issues, but the data of Randi et al. 
(2006) also point out this complexity.
The major goal of most epidemiolo-
gists working in the area of melanoma is 
to truly understand its etiology. The prob-
lem with the high-profile data presented 
by Whiteman et al. (2003) and Curtin et 
al. (2005) is that they are based on highly 
selected populations and divide melano-
mas rather abruptly between those on the 
head and neck and those on the trunk. 
Our study (Berwick et al., 2005), using 
the data cited in Table 1, found that sun-
damaged skin, as evidenced by solar 
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 Different etiologic 
pathways may 
consist of (1) aberrant 
melanogenesis and 
(2) cumulative sun 
exposure among 
susceptible individuals.
elastosis, appears all over the body and 
is in fact most significantly associated 
with melanoma on the trunk. Therefore, 
a paper such as that of Randi et al. (2006) 
is an important contribution to the litera-
ture, as it adds the necessary complexity 
to the important hypothesis put forth by 
Whiteman et al. (2003).
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Table 1. Comparison of anatomic distribution of melanoma and median number of nevi in case-control studies in 
Italy, Australia, and the United States
Randi et al. (2006), Italy Whiteman et al. (2003), 
Australia
Berwick et al., US
Total subjects 538 231 528
Head and neck 81 77 36
Trunk 219 154 284
 Upper extremities 48 —
 Lower extremities 183 —
Total extremities 231 — 189
Mean/median number of nevi Mean (trunk, head and neck, and upper extremities):
males, 20.2 females, 14.7
Median (trunk, head and neck, 
and upper extremities): 33
Median (back and arms): 5
Mean: 10.7
